A Study to Evaluate Safety and Efficacy of Radiopharmaceutical IR-101 in Patients With Relapsed or Refractory Neuroblastoma
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY
Radiopharmaceutical in Relapsed/Refractory Neuroblastoma
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Healthy Volunteers: f
View:
• Relapsed or refractory high-risk neuroblastoma with MIBG avid lesions in accordance with the Revised International Neuroblastoma Response Criteria (INRC);
• All soft-tissue lesions detected on CT/MRI must be MIBG-avid;
• Age ≥12 months;
• Lansky performance status ≥50%;
• Adequate organ function and hematologic parameters;
Locations
Other Locations
China
West China Hospital
RECRUITING
Chengdu
West China Hospital
RECRUITING
Chengdu
Contact Information
Primary
Rong Tian, MD
rongtiannuclear@126.com
18980601586
Time Frame
Start Date: 2025-07-18
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 10
Treatments
Experimental: Dose Escalation
Study drug IR-101 Dose Escalation
Related Therapeutic Areas
Sponsors
Leads: Sichuan University